TNFRSF25 and laryngotracheoesophageal cleft: The DR3 promoter methylation are shown that HBV-ACLF patients (median 56.13%, 48.47%–63.26%) was significantly lower than that in patients with HBV-LC (median 57.32%, 52.29%–63.57%, P < 0.001).